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Abstract. Few studies exist that consider 
multiple  myeloma  (MM)  undergoing  tandem  autologous  stem  cell  transplantation  (TASCT). 
Eighteen patients with advanced MM who underwent dose
study between March 2006 and March 2008. Patients <60 year old (10) received conditioning with 
melphalan 140 mg/m
2 and patients who were 
was  57.5  years  (range  35-69).  We  conducted  the  European  Organization  of  Research  and 
Treatment of Cancer (EORTC) QLQ
presentation, after each ASCT and thereafter every 3 months for 24 months. Mean global health 
measure improved from 3.44 before transplant to 4.50 
subsequent follow-up visits (P<0.001) and the mean global quality of life score improved from 3.61 
to  4.71  (P<0.001).  Pain  symptom
(P<0.001) throughout the period of post
TASCT  is  well  tolerated  with  low  toxicity  albeit  the  transient  reduction  in  QoL  during  both 
transplants.  Post-transplant  follow
reflects positively on the overall disease
does not adequately provide indication regarding the tolerability and effectiveness of a proposed 
treatment on the patient’s perceived quality of life. As clinicians, our primary c
toward  patient-welfare  as  well  as  survival.  Therefore,  we  should  employ  the  tools  of  QoL  in 
conjunction  with  overall  survival  in  order  to  deliver  the  best  possible  patient  outcomes.  The 
EORTC-QLQ-MY24 is a practical tool in measuring QoL i
Introduction. Multiple  myeloma  (MM)  is  a  chronic 
incurable  disease  that  is  associated  with  reduced 
quality  of  life.  This  is  in  part  due  to  chronic  pain 
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Few studies exist that consider health-related quality of life (HR
multiple  myeloma  (MM)  undergoing  tandem  autologous  stem  cell  transplantation  (TASCT). 
Eighteen patients with advanced MM who underwent dose-modified TASCT were enrolled in this 
06 and March 2008. Patients <60 year old (10) received conditioning with 
and patients who were ≥60 years (8) received 100 mg/m
69).  We  conducted  the  European  Organization  of  Research  and 
nt of Cancer (EORTC) QLQ-C30 and the QLQ-MY24 questionnaires via interviews at 
presentation, after each ASCT and thereafter every 3 months for 24 months. Mean global health 
measure improved from 3.44 before transplant to 4.50 (1=very poor, 7=excellent) 
up visits (P<0.001) and the mean global quality of life score improved from 3.61 
to  4.71  (P<0.001).  Pain  symptoms were reduced  (P=0.001),  and  physical  functioning  improved 
(P<0.001) throughout the period of post-transplant follow-up. Our study showed that dose
TASCT  is  well  tolerated  with  low  toxicity  albeit  the  transient  reduction  in  QoL  during  both 
transplant  follow-up  showed  significant  improvement in  overall  HR
e overall disease-outcome. Furthermore, a sole focus on patient
does not adequately provide indication regarding the tolerability and effectiveness of a proposed 
treatment on the patient’s perceived quality of life. As clinicians, our primary c
welfare  as  well  as  survival.  Therefore,  we  should  employ  the  tools  of  QoL  in 
conjunction  with  overall  survival  in  order  to  deliver  the  best  possible  patient  outcomes.  The 
is a practical tool in measuring QoL in myeloma patients.
Multiple  myeloma  (MM)  is  a  chronic 
incurable  disease  that  is  associated  with  reduced 
quality  of  life.  This  is  in  part  due  to  chronic  pain 
associated with osteolytic lesions, recurrent infections 
due to their immunocompromized status in addition to 
the side effects of different lines of treatment used to 
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related quality of life (HR-QoL) in patients with 
multiple  myeloma  (MM)  undergoing  tandem  autologous  stem  cell  transplantation  (TASCT). 
modified TASCT were enrolled in this 
06 and March 2008. Patients <60 year old (10) received conditioning with 
≥60 years (8) received 100 mg/m
2. The median age 
69).  We  conducted  the  European  Organization  of  Research  and 
questionnaires via interviews at 
presentation, after each ASCT and thereafter every 3 months for 24 months. Mean global health 
(1=very poor, 7=excellent) at the second and 
up visits (P<0.001) and the mean global quality of life score improved from 3.61 
reduced  (P=0.001),  and  physical  functioning  improved 
Our study showed that dose-reduced 
TASCT  is  well  tolerated  with  low  toxicity  albeit  the  transient  reduction  in  QoL  during  both 
up  showed  significant  improvement in  overall  HR-QoL  that 
Furthermore, a sole focus on patient-survival 
does not adequately provide indication regarding the tolerability and effectiveness of a proposed 
treatment on the patient’s perceived quality of life. As clinicians, our primary concern should be 
welfare  as  well  as  survival.  Therefore,  we  should  employ  the  tools  of  QoL  in 
conjunction  with  overall  survival  in  order  to  deliver  the  best  possible  patient  outcomes.  The 
n myeloma patients.
associated with osteolytic lesions, recurrent infections 
due to their immunocompromized status in addition to 
e effects of different lines of treatment used to Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
control  this  disease  including  autologous  stem  cell 
transplantation (ASCT).
1-4
ASCT  is  a  well  recognized  standard  therapy  for 
advanced myeloma disease with variable toxicities and 
considerable  effects  on  quality  of  life.
5-8 The  use  of 
melphalan  high-dose  therapy  (200  mg/m
2)  presents 
significant side effects and subsequently a reduction of 
quality  of  life  mainly  due  to  infections,  mucositis, 
increased use of blood products and prolonged stay in 
hospital.
7-8
There  are  few  studies  that  have  analyzed  health-
related quality of life (HR-QoL) in  conjunction with 
outcome and prognosis in patients with myeloma, who 
undergo  ASCT.
9-11 The  European  Organization  for 
Research and Treatment of Cancer (EORTC) Quality 
of Life Group’s questionnaire for evaluating quality of 
life  in  cancer  patients  has  been  used  in  over  3000  
international clinical trials. The latest (3
rd) version, the 
EORTC  QLQ-C30,  was  employed  in  this  study, 
supplemented  by  the  myeloma-specific  module,  the
QLQ-MY24 after  special  permission  from  the 
European Organization of Research and Treatment of 
Cancer.
10-11
We  prospectively  studied  18  Caucasian  patients 
with  multiple  myeloma  (MM)  who  were  planned  to 
receive  dose-reduced  melphalan  followed  by 
autologous tandem stem cell transplantation with three 
months between each transplant. The aim of the study 
is to assess HR-QoL in these patients in conjunction 
with  the  outcome  of  their disease  as well  as  overall 
survival.  We assessed the participants HR-QoL before
the transplant to evaluate the impact of symptomatic 
myeloma  on  QoL,  and  subsequently,  after  each 
transplant periodically every 3 months for 24 months, 
to  study  the  effect  of  dose-reduced  ASCT  and  its 
prognostic significance on various dimensions of QoL. 
Patient  and  Methods.  We  studied  18  patients 
diagnosed with multiple myeloma (MM) according the 
World  Health  Organization  (WHO)  criteria,  who 
underwent  tandem  ASCT  during  the  period  from 
March 2006 to March 2008. 
The trial was approved by the Tasmanian Human 
Research Ethics Committee, Australia.  An informed 
written  consent  was  obtained  from  all  participants 
according to code of Ethics. The study was registered 
in  the  Australia  and  New  Zealand  Clinical  Trial 
Registry  (ANZCTR)  website 
http://www.ANZCTR.org.au/ACTRN12609000595213
.aspx. 
The tandem transplants were performed 3 months 
apart  with  dose-reduced  melphalan,  100  mg/m
2 for 
elderly patients ≥60 years and 140 mg/m
2 for those <60 
years of age  followed by stem cell rescue in order to 
minimize  the  transplant  associated  toxicities.    All 
patients  presented  during  the  study  period  with 
advanced  MM  according  to  the  WHO  criteria  and 
undergoing  tandem-ASCT  were  recruited  in  this 
prospective study.  The male to female ratio was 16:2. 
The median age at first transplant was 57.5 years with 
an age range of (35-69). The patients were followed up 
for  a  median  period  of  35  months  post  transplant 
(range  29-49).  A  full  patient  profile  was  collected, 
including  demographic  and  medical  data  and  risk 
factors for multiple myeloma. Two patients succumbed 
at 22 and 26 months post transplant. The median time 
of follow up after diagnosis was 47.5 months (Range 
35-81) (Table 1).
Table 1.  Patient characteristics.
No. of patients 18
Median age (range)
>60
<60
57.5 (35-69)
8
10
Sex (M : F) 16 : 2
Stage of myeloma disease according Durie & 
Salmon
IIIA
IIIB
17
1
Type of myeloma:
IgG
IgA 
Light Chain
12
2
4
Transplant
Upfront therapy
After achieving remission in a relapsed disease 
16
2
Chemotherapy regimen prior Tx
VAD
Dexamethasone and Thalidomide
Velcade
Lenalidomide
3
9
4
2
Time followed up since diagnosis (Months) 47.5 (35-81)
Time followed up since First transplant (Months) 35 (29-49 )
High risk disease; stage III with hypercalcaemia, 
renal failure, high B2 Microglobulin
High cytogenetic risk ( e.g. 13q-, 17p-, t(4,14))
Patients with stage III disease with standard risk 
factors
8
6
4
Outcome of the disease
Alive 
Complete remission
Partial remission  
Deceased due to disease progression 
16
4
12
2
HR-QoL  was  measured  as  baseline  at  start  of 
treatment before the transplant to evaluate the impact 
of  symptomatic  myeloma  on  QoL,  and  subsequently 
after each transplant. Thereafter HR-QoL was assessed 
quarterly for 24 months period to study the effect of 
disease and ASCT and its prognostic significance on 
various dimensions of QoL. We hypothesized that the 
interval  between  QoL  measurements of  three  month 
should  be  adequate to  record  changes  in  QoL.  This 
gives an adequate time for the patients to observe and Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
record the changes of their QoL without a longer recall 
period  that  may  substantiate  unnecessary  bias.    Our 
study utilizes version 3.0 of the EORTC QLQ-C30 and 
the  QLQ-MY24 (Multiple  Myeloma  Module) 
questionnaires  with  permission  from  the  EORTC, 
presented longitudinally to a sample of Australian MM 
patients pre- and post-ASCT.
10-11
Methods. The  EORTC  quality  of  life  questionnaire 
(QLQ) is an integrated system for assessing the HR-
QoL  of  cancer  patients  participating  in  international 
clinical trials.  The core questionnaire, the QLQ-C30, 
is the product of more than a decade of collaborative 
research. Following its general release in 1993, a large 
number  of  research  groups  have used  the  EORTC 
QLQ-C30  and  the  QLQ-MY24  in  a  wide  range  of 
oncology clinical trials; additionally, it has been used 
in various other non-trial studies. The EORTC QLQ-
C30 is composed of functional and physical assessment 
as well as the global health measure. It covers general 
aspects of health-related quality of life and additional 
disease or treatment-specific questionnaire modules.
10-
11  Raw  EORTC  Quality  of  Life  QLQ-C30  and the 
QLQ-MY24  questionnaires  data  were  linearly
converted  to  give  standard  scores into  scales  with 
ranges from 0 to 100 for each of the scales and single 
items. Accordingly, in the QoL scale; 0 represents the 
worst  functioning  quality  of  life  and  100  the  best 
quality  of  life.  While  in  the  symptoms  scales;  0 
represents  absence  of  symptoms  and  100  represents 
maximum presence of symptoms. 
The myeloma module of EORTC QLQ-C30 (QLQ-
MY24) that has been used here is designed for patients 
with MM to assess the symptoms and side effects of 
treatment  and  their  impact  on  everyday  life.
10 The 
module  comprises  24  questions  addressing  four 
domains of QoL important in myeloma: a pain scale, 
treatment  side  effects,  social  support  and  future 
perspective. The module was developed according to 
the guidelines and approved after formal review.
10,11
The  EORTC  Quality  of  Life  QLQ-C30  and  the 
QLQ-MY24 questionnaire (myeloma specific module) 
was presented to all patients at interview before, during 
and after each transplant and regularly thereafter every 
3 months in the first 24 months post transplant, by a 
research assistant who underwent special training with 
the specific QLQ-C30 and QLQ-MY24 modules. 
Statistical Analysis. EORTC Quality of Life QLQ-C30 
and  the  QLQ-MY24  scales  are rank-order  data 
(ordered  data  but  without  fixed  interval  sizes  across 
their range). Estimation of the changes of the data over 
time was performed using repeated-measures in ordinal 
logistic  regression  of  those  scale  data  over  time:  1) 
each  measurement  point was  compared to  the  initial 
measurement without assuming linearity of time; and 
also 2) the association of each measurement with time 
was assessed by non-linear regression using a 2
nd-order 
polynomial model (time and time-squared in order to 
determine  whether  changes  during  treatments  were 
reversed  in  the  follow-up  period).  Results  were 
expressed  as:  1)  odds  ratios  with  95%  confidence 
intervals  and  p-values  corrected  for  multiple 
comparisons by the Holm method; and 2) p-values for 
non-parametric  trend  for  time  (T)  and  time-squared 
(T
2). Rate of mortality was estimated by the Mantel-
Cox  method  (and  time-to-event  graphs  for  mortality 
were constructed) using death, loss to follow-up and 
completion of 48 months follow-up as censoring times. 
All  analyses were performed using Stata/IC 10.1 for 
Windows (StataCorp LP, College Station, Tx, USA). 
Results. Physical, social, emotional, role and cognitive 
functions were analyzed and scored to four groups as 
those with severe, moderate, mild and no dysfunction. 
The gastrointestinal symptoms; loss of appetite, nausea 
and vomiting, constipation and diarrhea were similarly 
classified as were dyspnea, pain, fatigue and insomnia. 
The financial disability to the patient was analyzed as 
was the Global Health Measure (GHM) and the Global 
Quality of Life (GQL) Score. 
Progress  of  Symptoms,  Functioning  and  Qol Scales 
Before, During and After ASCT. Changes in symptom 
levels  were  summarized  in  Figure  1.  The  dominant 
symptoms present prior to the first ASCT were pain 
and fatigue. During the peri-treatment period there was 
a reduction in pain scores (OR 0.11; 95% CI 0.03 to 
0.43;  P  for  trend  T=0.001  T
2=0.004),  but  levels  of 
fatigue  increased  (OR  2.97;  95%  CI  1.05  to  8.38; 
T=0.16 T
2=0.009). Levels of anorexia (OR 7.15; 95% 
CI  1.98  to  25.9;  T=0.028  T
2=0.025),  nausea  and 
vomiting  (OR  3.12;  95%  CI  0.84  to  11.5;  T=0.08 
T
2=0.03),  abdominal  discomfort  (OR  3.57;  95%  CI 
1.07  to  11.9; T=0.06 T
2=0.045)  as well  as  insomnia 
(OR  6.92;  95%  CI  0.82  to  58.1;  T=0.09  T
2=0.08) 
increased  during  treatment.  In  addition,  there  was  a 
trend to  rise in  dyspnea and diarrhea symptoms, but 
these  did  not  reach  statistical  significance  in  the 
patients observed. All the worsening of symptoms that 
occurred  during  transplant  were  reversed  at  the  first 
and  second  3-monthly  follow-up  assessments  and 
remained  improved  without  change  in  subsequent 
follow-ups.  The  fatigue  also  improved  compared  to 
pre-treatment levels (OR 0.16; 95% CI 0.04 to 0.70; 
P=0.05),  pain  improved  at  substantially  lower  levels 
(OR 0.18; 95% CI 0.06 to 0.54; P=0.005), and other 
symptoms  returned to  their  apparently  low  pre-
transplant levels (Table 2).
Changes in levels of functioning and global health Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Percentile distribution 
of symptom scores (pain, fatigue 
and loss of appetite) and quality 
of  life  scores  (physical 
functioning,  global  health  and 
global  Quality  of  Life)  at 
different times of treatment with 
tandem  autologous  stem  cell 
transplants in 18 patients treated 
for  multiple  myeloma. P-values 
for  trend  were  estimated  by 
repeated-measures,  second-order 
polynomial  {time  (T)  and  time
2
(T
2)}, ordinal logistic regression. 
Trend  lines  were  estimated  by 
repeated-measures,  second-order 
polynomial,  general  linear 
modeling for illustrative purposes 
only.  In  the  QoL  scale;  0 
represents  the  worst  functioning 
quality  of  life  and  100  the  best 
quality  of  life,  while  in  the 
symptoms  scales;  0  represents 
absence  of  symptoms  and  100 
represents maximum presence of 
symptoms.
and quality  of  life  measures  were  also  described  in 
Figure 1. Physical (OR 6.78; 95% CI 2.81 to 16.4; P 
for  trend T<0.001) and social functioning (OR 3.16; 
95%  CI  1.42  to  7.02;  T=0.021  T
2=0.009)  were 
moderately improved in the follow-up period, as well 
as the patient’s assessment of their global health status
(OR 7.99; 95% CI 2.67 to 23.9; P for trend T<0.001) 
and quality of life (OR 7.06; 95% CI 2.74 to 18.2; P for 
trend  T<0.001)  and  remained  the  same  in  the  3 
monthly  follow  up.  Of  interest,  patients  reportedMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Progress of functioning and quality of life in patients receiving tandem autologous stem cell transplantation for multiple myeloma
EORTC QLQ-C30 Scale
1 Mean (SD) Mean Difference
2 OR
3 95% CI P-value
4
Physical functioning
Pre-transplant 57.5 (25.2) 1.00 (T:<0.001)
After 1
st Tx 67.8 (30.8) 10.3 2.48 (0.78 to 7.89) 0.25
After 2
nd Tx 66.7 (30.7) 9.2 2.22 (0.77 to 6.36) 0.14
1
st Follow-up 83.8 (18.2) 26.3 6.78 (2.81 to 16.4) <0.001
2
nd and subsequent Follow-up  83.8 (16.7) 26.3 6.40 (2.00 to 20.5) 0.005
Role functioning
Pre-transplant 56.3 (25.0) 1.00 (T:0.38 & T
2:0.68)
After 1
st Tx 52.8 (36.3) -3.5 0.84 (0.26 to 2.77) >0.9
After 2
nd Tx 52.8 (40.1) -3.5 0.86 (0.24 to 3.05) 0.81
1
st Follow-up 90.6 (20.2) 34.4 12.43 (3.45 to 44.8) 0.001
2
nd and subsequent Follow-up 65.6 (23.9) 9.4 1.70 (0.74 to 3.90) 0.63
Cognitive functioning
Pre-transplant 72.9 (28.5) 1.00 (T:0.43 & T
2:0.47)
After 1
st Tx 66.7 (23.6) -6.3 0.52 (0.19 to 1.46) 0.86
After 2
nd Tx 67.6 (21.0) -5.3 0.56 (0.19 to 1.62) 0.86
1
st Follow-up 72.2 (20.6) -0.7 0.81 (0.39 to 1.70) 0.58
2
nd and subsequent Follow-up 67.7 (32.5) -5.2 0.71 (0.31 to 1.64) 0.84
Emotional functioning
Pre-transplant 81.3 (27.1) 1.00 (T:0.91 & T
2:0.96)
After 1
st Tx 83.8 (19.7) 2.5 0.88 (0.24 to 3.23) >0.9
After 2
nd Tx 83.8 (19.9) 2.5 0.95 (0.25 to 3.58) 0.94
1
st Follow-up 92.2 (13.5) 11.0 2.13 (0.79 to 5.76) 0.55
2
nd and subsequent Follow-up 83.9 (26.4) 2.6 1.27 (0.52 to 3.11) >0.9
Social functioning
Pre-transplant 62.5 (15.5) 1.00 (T:0.021& T
2:0.009)
After 1
st Tx 51.9 (27.3) -10.6 0.42 (0.17 to 1.03) 0.18
After 2
nd Tx 52.8 (26.4) -9.7 0.45 (0.19 to 1.07) 0.14
1
st Follow-up 65.6 (25.6) 3.1 1.25 (0.35 to 4.44) 0.73
2
nd and subsequent Follow-up 76.0 (18.2) 13.5 3.16 (1.42 to 7.02) 0.019
Financial difficulties
Pre-transplant 29.2 (29.5) 1.00 (T:0.008 & T
2:0.003)
After 1
st Tx 48.1 (38.3) 19.0 2.55 (0.93 to 6.96) 0.21
After 2
nd Tx 48.1 (38.3) 19.0 2.55 (0.93 to 6.96) 0.21
1
st Follow-up 26.7 (31.4) -2.5 0.84 (0.30 to 2.38) 0.74
2
nd and subsequent Follow-up 12.5 (24.0) -16.7 0.28 (0.10 to 0.81) 0.077
Global health status
Pre-transplant 38.5 (25.6) 1.00 (T:<0.001)
After 1
st Tx 40.7 (23.7) 2.2 1.17 (0.40 to 3.40) 0.78
After 2
nd Tx 45.4 (24.8) 6.8 1.81 (0.61 to 5.33) 0.57
1
st Follow-up 61.1 (23.3) 22.6 5.51 (1.30 to 23.3) 0.061
2
nd and subsequent Follow-up 65.6 (15.5) 27.1 7.99 (2.67 to 23.9) 0.001
Global QoL
Pre-transplant 41.7 (29.2) 1.00 (T:<0.001)
After 1
st Tx 43.5 (27.5) 1.9 1.22 (0.47 to 3.20) 0.68
After 2
nd Tx 48.1 (30.7) 6.5 1.77 (0.66 to 4.74) 0.51
1
st Follow-up 71.1 (20.4) 29.4 7.12 (2.23 to 22.7) 0.003
2
nd and subsequent Follow-up 70.8 (18.8) 29.2 7.06 (2.74 to 18.2) <0.001
EORTC Quality of Life Functioning Scales: each have a range of 0-100 with 0 being worst functioning and 100 best functioning. Mean 
difference QoL scale scores at specified times compared to initial pre-transplant assessment, estimated by general linear modelling (GLM) 
corrected for repeated measures (this treats the scale scores as continuous interval data, which is not appropriate, but shown for illustrative 
purposes only). Comparison of QoL scale scores at specified times compared to initial pre-transplant assessment, estimated by ordinal 
logistic regression (OLR) corrected for repeated measures and expressed as odds ratio with 95% confidence intervals and P-values (OLR is a Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
non-parametric version of GLM that treats the scale scores as rank order data). P-values shown are: 1) in the Pre-transplant row, the P-value 
for 2
nd-order  polynomial trend  (T=time,  and  T
2=time-squared)  demonstrating  (or  not)  the reversal of the  effects of  the  receiving  dual 
autologous stem cell transplant; and 2) in subsequent rows, the comparisons of the other time periods to the pre-transplant assessment 
corrected for multiple comparisons by the Holm method (against the OR 1.00, all estimated by OLR which does not assume linearity of time)
increased  financial  difficulties  during  transplant,  and 
also  somewhat  reduced  social  functioning,  which 
recovered  during  follow-up  assessments.  Role, 
cognitive  and  emotional  functioning  appeared  to  be 
unaltered  throughout  the  assessment  periods.  There 
was a steady rise in physical functioning, mirrored by a 
steady rise in global health status and quality of life. 
Furthermore, it seems that the psychosocial dimensions 
of QoL did not change with the alterations of disease-
status  during  the  period  of  follow  up;  however, 
physical QoL and global QoL were closely linked and 
affected by disease-status (Table 2).
Patient  Survival  Following  Diagnosis  of  Multiple 
Myeloma.  Patients  were  followed-up  for  a  median 
period of 35 months (median; range 29 to 49 months). 
Two  patients  died  at  22  and  26  months,  with  an 
estimated  mortality  rate  of  5.3%  per  year  (95% 
confidence intervals 1.3 to 21.1 % per year).  After a 
median  follow  up  period  of  35  months,  16  patients 
were alive and 16 remained in remission; 4 in complete 
remission (CR), 12 in partial remission  (PR), while 2 
patients  experienced  further  disease  progression  and 
succumbed  at  22  and  26  months  of  follow  up  post-
transplant (Figure 2). 
Figure 2. Overall survival in the months following treatment with 
dose-reduced  tandem  ASCT  in  18  patients  treated  for  multiple 
myeloma
Discussion. Our study provided further evidence of the 
significant  impairment  of  HR-QoL in  patients  with 
multiple myeloma at onset of therapy.
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In our  series,  the  main symptoms prior  to  ASCT 
that  myeloma  patients  presented with  were pain  and 
fatigue,  while  during  the  peri-treatment  period  there 
was a reduction in pain scores with increased fatigue. 
This  is  largely  due  to  the  direct  effect  of  the 
intermediate  to  high-dose  chemotherapy  on  the 
hemoglobin  levels  causing  a  transient  anemia.  In 
contrast,  the  pain  scores  improved  due  to  several 
factors  including  effective  control  of  the  disease in 
addition  to  employing  pain  medications  during  the 
active treatment period (p=0.004). Furthermore, levels 
of  nausea,  vomiting,  abdominal  discomfort  and 
insomnia increased temporarily during ASCT, mostly 
due to the adverse effect of intermediate to high dose 
melphalan.  All  the  worsening  of  symptoms  that 
occurred during the transplant were reversed at the first 
or  second  3-monthly  follow-up  assessment  and 
remained stable in subsequent follow-ups. Moreover, 
the  level  of  fatigue  improved  compared  to  pre-
transplant levels (p=0.05) with the pain remaining at 
substantially  significant  lower  levels  (p=0.006) 
compared to the pre-transplant period. Other symptoms 
returned to their pre-transplant levels.
Physical  and  social  functioning  was  moderately 
improved in the 3 monthly follow-up period, as was the 
patient’s assessment of their global health status and 
quality  of  life.  Interestingly,  MM  patients  reported 
increased financial difficulties during the ASCT period 
(p=0.07)  as  well  as  reduced  social  functioning 
(p=0.05).    However, this  improved during  follow-up 
assessments.  There  was  a  steady  rise  in  physical 
functioning, reflected by a steady rise in global health 
status and quality of life (p=0.001). Role, cognitive and 
emotional  functioning  appeared  to  be  unaltered
throughout the assessment periods. We observed that 
the psychosocial dimensions of QoL were found to be 
independent  factors,  while  physical  QoL  and  global 
QoL  were  affected  by  disease  progression. 
Furthermore,  our  data  showed  a  good  correlation 
between  physical  QoL  scales  such  as  pain,  fatigue, 
physical  functioning  and  global  QoL  than  between 
psychosocial  dimensions  such  as  role,  emotional, 
social,  and  cognitive  functioning  in  accordance  with 
other  studies  with  improved  QoL  measures  in  our 
series compared to the standard high-dose ASCT.
15-17
A  multivariate  analyses  by  Prieto  and  colleagues 
revealed that higher systemic symptomatology scores 
were  significantly  associated  with  impaired  overall 
quality  of life with a  higher psychosocial distress  in 
patients  undergoing  stem  cell  transplantation.
20 
However, in the new era of novel agents for treatment 
of MM such as proteasome inhibitor; bortezomib and 
the  immunomodulatory  agents;  thalidomide  and 
lenalidomide,  there  is  a  significant  improvement  of 
quality  of  life  in  the  management  of  older  patients 
and/or those not eligible for transplantation.
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Our study has a few shortcomings. First, it has a 
relatively  small  number  of  patients;  therefore  it  is 
difficult to draw a concrete conclusion, however, due 
to  lack  of  data  in  this  regard,  it  is  worthwhile 
documenting  such  results.  Second,  owing  to  the 
inherent difficulties in measuring quality of life, there 
is  no  dedicated  control  group  for  patients  who  have 
received a single transplant with high dose melphalan, 
so that the very few published data from other cohorts 
are being used as the point of reference.
20
Conclusions. Our  analysis  shows  that  dose-modified 
tandem ASCT is well tolerated with acceptable toxicity 
and side effects albeit the transient impairment in QoL 
during  both  transplants.  Nevertheless,  the  post 
transplant follow up showed significant improvement 
in the quality of life that certainly reflects positively in 
the overall disease outcome. Furthermore, the present 
study confirmed the EORTC QLQ-C30 with the QLQ-
MY24  questionnaires to  be a  practical  instrument  in 
measuring the QoL in patients with advanced myeloma 
disease both before and after treatment.  After a median 
follow  up  of  35  months, 16  patients  were alive  and 
remained in remission (4 CR, 12 PR).
Clearly, a sole focus on patient’s survival does not 
necessarily reflect the tolerability and effectiveness of 
a proposed treatment on the patient’s perceived quality 
of  life.
19,20 Therefore,  measures  of  overall  survival 
should be employed in conjunction with the impact on 
health-related  quality  of  life  to  achieve  the  best 
possible outcomes. 
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